The Trump administration announced most-favored-nation (MFN) pricing agreements with Eli Lilly and Novo Nordisk for GLP-1 drugs in 2026. For patients paying $900–$1,300 per month for Ozempic, Wegovy, and Zepbound, here is what the TrumpRx MFN pricing agreements actually mean for what you'll pay in 2026.
Most-favored-nation (MFN) pricing means the United States pays no more for a drug than the lowest price any other developed country pays for that same drug. Under TrumpRx, the Trump administration announced MFN pricing agreements with Eli Lilly and Novo Nordisk — guaranteeing MFN prices on GLP-1 medications including Wegovy, Zepbound, Ozempic, and Mounjaro for U.S. patients through the TrumpRx platform.
MFN pricing has been debated in Washington for years. GLP-1 drugs like Ozempic and Wegovy are sold in Germany, France, and other developed countries at prices 50–80% lower than U.S. list prices. MFN pricing — if fully implemented — brings those international reference prices to U.S. patients directly through TrumpRx.gov and manufacturer direct-to-consumer channels.
GLP-1 medications covered include: Wegovy (semaglutide) and Ozempic (semaglutide) from Novo Nordisk; Zepbound (tirzepatide) and Mounjaro (tirzepatide) from Eli Lilly. Eli Lilly also offers a Zepbound coupon and savings card for commercially insured patients. The Trump administration announced binding agreements with Eli Lilly and Novo Nordisk to guarantee MFN prices on these GLP-1 drugs for U.S. patients. The target price for eligible medications is approximately $389 per month.
The $389 per month figure cited in administration fact sheets and media reporting represents the target MFN price point — a significant reduction from current U.S. list prices of $900–$1,300 per month for Wegovy and Zepbound. Actual prices available through TrumpRx.gov depend on the specific drug, dose, and manufacturer program terms at time of access.
| GLP-1 Drug | U.S. List Price | TrumpRx MFN Target | Est. Savings |
|---|---|---|---|
| Wegovy (semaglutide) | ~$1,300/month | ~$389/month | ~70% |
| Ozempic (semaglutide) | ~$900/month | MFN-based | Varies |
| Zepbound (tirzepatide) | ~$1,060/month | ~$389/month | ~63% |
| Mounjaro (tirzepatide) | ~$1,060/month | MFN-based | Varies |
TrumpRx GLP-1 pricing is a direct-to-consumer program that operates outside insurance and pharmacy benefit managers. Patients access GLP-1 drugs at MFN prices directly through manufacturer programs listed on TrumpRx.gov. Key details:
GLP-1 pricing options in 2026 are more varied than ever. Compare all of these before deciding which path to take:
Always compare your total out-of-pocket cost across all available options before filling a GLP-1 prescription. Use RxDiff's GLP-1 savings guide to see current pricing and program comparisons for Ozempic, Wegovy, and other GLP-1 medications available in 2026.
Compare all GLP-1 pricing options including TrumpRx — free on RxDiff.
Explore GLP-1 Savings on RxDiff →The current price depends on the exact program offer, medicine, dose, patient eligibility, and fulfillment costs. Verify the live terms rather than relying on a headline price.
Availability and eligibility depend on the current offer and exact product. Confirm the medication and dose on the program’s current list.
No. Safety, diagnosis, dose, authenticity, follow-up, and total cost all matter. Discuss alternatives with your prescriber and pharmacist.
For authoritative information, see the CMS Newsroom. The Centers for Medicare and Medicaid Services (CMS) published official guidance on Medicare GLP-1 drug coverage and the Most Favored Nation pricing framework.
Medical Disclaimer: This content is for informational purposes only. Drug prices change frequently — always verify current pricing at your pharmacy before filling. Consult your healthcare provider or pharmacist about your specific medications.